Divis Laboratories Ltd Q4 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/scky776gn4qkkbc9f8mq9qvi.pdf

Key Takeaways


Margin Walk & Raw Material Transition

Dr. Murali K Divi: "It's difficult to say exactly when on quarter-on-quarter, but we should be able to see that towards the end of the year."

Custom Synthesis: The Growth Engine

Dr. Murali K Divi: "We are seeing several other opportunities in custom synthesis projects from big pharmas, never seen so many opportunities."

Generic API: Destocking, Then Recovery

Dr. Murali K Divi: "After the COVID impact, there are huge stocks of dosage forms and the dosage form companies' generics, they're fighting for getting rid of the stocks before the expiry date. And hence there is a crash in the prices of generic dosage forms and less demand for the generic APIs because they don't need, first they want to get rid of. But once that happens, they need APIs again. So I expect the prices to stabilize and we should see improvement in the coming quarters."

Unit 3 (Kakinada): The Next Decade's Foundation

Dr. Murali K Divi: "Having done all this now, we are very comfortable in looking at for the next three years, five and 10 years. Otherwise, I wouldn't invest INR 1,200 crores to INR 1,500 crores in Unit 3..."

Operational Context & Competitive Position

Dr. Murali K Divi: "There is nothing that happened like sky is falling down. So there's nothing unprecedented thing that happened. I think it's the general course that took place where always I used to say for the last several years, you should not judge the company by quarter-on-quarter..."

Guidance & Commitments

CommitmentSpecificsTimeline
Gross margin normalizationReturn toward historical levels of 67–68%"Towards the end of the year" (FY24)
Raw material cost improvementBenefits from softening input prices to begin flowing throughFrom Q1 FY24 onward
New custom synthesis revenueTwo large projects (one sartan, one unnamed) to reflect in revenue"Coming quarters"
Unit 3 Phase 1 commercializationProduction to begin at Kakinada greenfield siteEnd of calendar year 2024
Unit 1/2 capacity unlockFreed-up GMP buildings to host new custom synthesis and generic productsBenefits visible from FY25
Generic capacity expansion payoffFull benefits from products where capacity was expanded to become #1/#24–8 quarters as end-customer qualifications progress
Generic API pricing recoveryStabilization and improvement after dosage-form destocking ends"Coming quarters"
Double-digit revenue growthEx-COVID one-time opportunity baselineOngoing expectation
Corporate tax rateNormalization as SEZ benefits phase out~25–27% over next 10–15 years

Key Metrics

MetricQ4 FY23
Consolidated total revenue₹2,017 cr, vs ₹2,571 cr in Q4 FY22
Constant currency revenue growth-32% YoY
Material consumption42% of sales revenue, vs 38–39% historically (per an analyst's math)
Profit before tax₹466 cr
Profit after tax₹321 cr
Exports share~90% of revenue
Exports to US and Europe~68% of revenue
Product mix (generics:custom synthesis)59:41
Nutraceutical business revenue₹150 cr
Forex loss₹4 cr
Capitalized assets₹480 cr
Capital work in progress~₹212 cr as of March 31, 2023
Cash on book₹4,136 cr as of March 31, 2023
Receivables₹1,793 cr as of March 31, 2023
Inventories₹3,000 cr as of March 31, 2023
Capacity utilization~77% to 80%
Unit 3 Phase 1 capex plan₹1,200 cr to ₹1,500 cr
Expected corporate tax rate~25% to 27% over next 10–15 years as SEZ benefits phase out